Single Center, Phase 2B, Randomized, Double Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of a Single Dose of Oral ALLOD-2 Versus Oral Sumatriptan in the Acute Treatment of Migraine With Associated Nausea in Adults (ANODYNE-2)

Trial Profile

Single Center, Phase 2B, Randomized, Double Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of a Single Dose of Oral ALLOD-2 Versus Oral Sumatriptan in the Acute Treatment of Migraine With Associated Nausea in Adults (ANODYNE-2)

Recruiting
Phase of Trial: Phase II/III

Latest Information Update: 21 Aug 2017

At a glance

  • Drugs ALLOD 2 (Primary) ; Sumatriptan
  • Indications Migraine with aura; Migraine without aura; Nausea
  • Focus Therapeutic Use
  • Acronyms ANODYNE-2
  • Sponsors Allodynic Therapeutics
  • Most Recent Events

    • 11 Jul 2017 Planned End Date changed from 27 Oct 2018 to 1 Oct 2018.
    • 11 Jul 2017 Planned primary completion date changed from 27 Jun 2018 to 1 Jun 2018.
    • 28 Jun 2017 Status changed from not yet recruiting to recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top